PFEPfizer
$28.07+1.01%Real quote · delayedPharma🏛️ Company factsSEC filings + FINRA official data
Annual revenue $62.6B · latest quarter up 2.6% YoY · profitable (FY net income $7.8B) · short activity above its recent average — bears adding.
FY revenue
$62.6B
2025-12
Latest Q YoY
+2.6%
FY net income
$7.8B
Diluted EPS
$1.37
Short volume
46.8%
20d avg 39% · shorts building
🐋 5%+ ownership filings (last 180d)
The parties below hold over 5% of this company and disclosed it to the SEC (mandatory in US markets). "Activist" filers state an intent to influence the company; "Passive" are pure investment positions.
- 2026-05-01passive (13G)VANGUARD CAPITAL MANAGEMENT LLC
- 2026-03-27passive (13G)VANGUARD GROUP INC
🎯 Market expectations
Expectation reliability Medium · 47/100Nasdaq analyst consensus · the pre-news baseline
- Jun 2026$0.77 vs $0.68+13.24%
- Mar 2026$0.75 vs $0.71+5.63%
- Dec 2025$0.66 vs $0.57+15.79%
- Sep 2025$0.87 vs $0.66+31.82%
This company habitually beats by +16.6% — the next report has to clear that bar to count as good news. Analysts cut estimates 3× in 4 weeks.
Analyst estimates, not our forecast · not investment advice
🕰️ Price × news · engine report card
Drag to pan, scroll to zoom · dot = engine's call · color = outcome, arrow = direction
📜 Call history (newest first
19 engine calls on this stock — each with direction, magnitude and its verified outcome · sign up to view
Sign up · free 7-day trial →Impact chains · crowding · conviction engine · insider signals — free 7-day trial on signup.
Sign up · free 7-day trial →